|
1
|
Armitage JO and Weisenburger DD: New
approach to classifying non-Hodgkin’s lymphomas: clinical features
of the major histologic subtypes. Non-Hodgkin’s Lymphoma
Classification Project. J Clin Oncol. 16:2780–2795. 1998.
|
|
2
|
Maxwell SA and Mousavi-Fard S:
Non-Hodgkin’s B-cell lymphoma: advances in molecular strategies
targeting drug resistance. Exp Biol Med (Maywood). 238:971–990.
2013.
|
|
3
|
Foss FM: Treatment strategies for
peripheral T-cell lymphomas. Best Pract Res Clin Haematol.
26:43–56. 2013.
|
|
4
|
Fisher RI, Gaynor ER, Dahlberg S, et al:
Comparison of a standard regimen (CHOP) with three intensive
chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J
Med. 328:1002–1006. 1993.
|
|
5
|
Gangatharan S and Kuruvilla J: Relapsed
and refractory aggressive NHL: time for a change. Transfus Apher
Sci. 49:72–79. 2013.
|
|
6
|
Lunning MA, Moskowitz AJ and Horwitz S:
Strategies for relapsed peripheral T-cell lymphoma: the tail that
wags the curve. J Clin Oncol. 31:1922–1927. 2013.
|
|
7
|
Peniket AJ, Ruiz de Elvira MC, Taghipour
G, et al: European Bone Marrow Transplantation (EBMT) Lymphoma
Registry: An EBMT registry matched study of allogeneic stem cell
transplants for lymphoma: allogeneic transplantation is associated
with a lower relapse rate but a higher procedure-related mortality
rate than autologous transplantation. Bone Marrow Transplant.
31:667–678. 2003.
|
|
8
|
Sinha R, Nastoupil L and Flowers CR:
Treatment Strategies for Patients with Diffuse Large B-Cell
Lymphoma: Past, Present, and Future. Blood Lymphat Cancer.
2012:87–98. 2012.
|
|
9
|
Mak V, Hamm J, Chhanabhai M, et al:
Survival of patients with peripheral T-cell lymphoma after first
relapse or progression: spectrum of disease and rare long-term
survivors. J Clin Oncol. 31:1970–1976. 2013.
|
|
10
|
Friedberg JW: Relapsed/refractory diffuse
large B-cell lymphoma. Hematology Am Soc Hematol Educ Program.
2011:498–505. 2011.
|
|
11
|
Raut LS and Chakrabarti PP: Management of
relapsed-refractory diffuse large B cell lymphoma. South Asian J
Cancer. 3:66–70. 2014.
|
|
12
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982.
|
|
13
|
Armitage JO: Staging Non-Hodgkin Lymphoma.
CA Cancer J Clin. 55:368–376. 2005.
|
|
14
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
|
|
15
|
Common Terminology Criteria for Adverse
Events v3.0 (CTCAE). Cancer Therapy Evaluation Program, Common
Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI,
NIH, DHHS. http://ctep.cancer.gov.
August 9–2006
|
|
16
|
Prichard M, Harris T, Williams ME, et al:
Treatment strategies for relapsed and refractory aggressive
non-Hodgkin’s lymphoma. Expert Opin Pharmacother. 10:983–995.
2009.
|
|
17
|
Velasquez WS, Cabanillas F, Salvador P, et
al: Effective salvage therapy for lymphoma with cisplatin in
combination with high-dose Ara-C and dexamethasone (DHAP). Blood.
71:117–122. 1988.
|
|
18
|
Gisselbrecht C, Glass B, Mounier N, et al:
Salvage regimens with autologous transplantation for relapsed large
B-cell lymphoma in the rituximab era. J Clin Oncol. 28:4184–4190.
2010.
|
|
19
|
Velasquez WS, McLaughlin P, Tucker S, et
al: ESHAP - an effective chemotherapy regimen in refractory and
relapsing lymphoma: a 4-year follow-up study. J Clin Oncol.
12:1169–1176. 1994.
|
|
20
|
Caballero MD, Amigo ML, Hernández JM, et
al: Alternating mini-BEAM/ESHAP as salvage therapy for refractory
non-Hodgkin’s lymphomas. Ann Hematol. 74:79–82. 1997.
|
|
21
|
Girouard C, Dufresne J, Imrie K, et al:
Salvage chemotherapy with mini-BEAM for relapsed or refractory
non-Hodgkin’s lymphoma prior to autologous bone marrow
transplantation. Ann Oncol. 8:675–680. 1997.
|
|
22
|
Moskowitz CH, Bertino JR, Glassman JR, et
al: Ifosfamide, carboplatin, and etoposide: a highly effective
cytoreduction and peripheral-blood progenitor-cell mobilization
regimen for transplant-eligible patients with non-Hodgkin’s
lymphoma. J Clin Oncol. 17:3776–3785. 1999.
|
|
23
|
Aurer I, Mitrović Z, Nemet D, et al:
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma
with two ifosfamide-based regimens, IMVP and ICE. J Chemother.
20:640–644. 2008.
|
|
24
|
Crump M, Baetz T, Couban S, et al:
Gemcitabine, dexamethasone, and cisplatin in patients with
recurrent or refractory aggressive histology B-cell non-Hodgkin
lymphoma: a Phase II study by the National Cancer Institute of
Canada Clinical Trials Group (NCIC-CTG). Cancer. 101:1835–1842.
2004.
|
|
25
|
Crump M, Shepherd L and Lin B: A
randomized phase III study of gemcitabine, dexamethasone, and
cisplatin versus dexamethasone, cytarabine, and cisplatin as
salvage chemotherapy followed by posttransplantation rituximab
maintenance therapy versus observation for treatment of aggressive
B-Cell and T-Cell non-Hodgkin’s lymphoma. Clin Lymphoma. 6:56–60.
2005.
|
|
26
|
Kuruvilla J, Nagy T, Pintilie M, et al:
Similar response rates and superior early progression-free survival
with gemcitabine, dexamethasone, and cisplatin salvage therapy
compared with carmustine, etoposide, cytarabine, and melphalan
salvage therapy prior to autologous stem cell transplantation for
recurrent or refractory Hodgkin lymphoma. Cancer. 106:353–360.
2006.
|
|
27
|
Hernandez-Ilizaliturri FJ and Czuczman MS:
Therapeutic options in relapsed or refractory diffuse large B-cell
lymphoma. Part 1 current treatment approaches. Oncology (Williston
Park). 23:546–553. 2009.
|
|
28
|
Wallace RE, Murdock KC, Angier RB and Durr
FE: Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis
((2-[(2-hydroxyethyl)amino]ethyl)amino)-9,10-anthracenedione
dihydrochloride, against experimental tumors in mice. Cancer Res.
39:1570–1574. 1979.
|
|
29
|
Armitage JO: The role of mitoxantrone in
non-Hodgkin’s lymphoma. Oncology (Williston Park). 16:490–502.
507–508; discussion 511–512, 514. 2002.
|
|
30
|
Coltman CA Jr, Coltman TM, Balcerzak SP,
et al: Mitoxantrone in refractory nonHodgkin’s lymphoma. A
Southwest Oncology Group study. Semin Oncol. 11(3 Suppl 1): 50–53.
1984.
|
|
31
|
Gams RA, Bryan S, Dukart G, et al:
Mitoxantrone in malignant lymphoma. Invest New Drugs. 3:219–222.
1985.
|
|
32
|
Silver RT, Case DC Jr, Wheeler RH, et al:
Multicenter clinical trial of mitoxantrone in non-Hodgkin’s
lymphoma and Hodgkin’s disease. J Clin Oncol. 9:754–761. 1991.
|
|
33
|
Chamorey E, Gressin R, Peyrade F, et al:
Prospective randomized study comparing MEMID with a chop-like
regimen in elderly patients with aggressive non-Hodgkin’s lymphoma.
Oncology. 69:19–26. 2005.
|
|
34
|
Mainwaring PN, Cunningham D, Gregory W, et
al: Mitoxantrone is superior to doxorubicin in a multiagent weekly
regimen for patients older than 60 with high-grade lymphoma:
results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Blood. 97:2991–2997. 2001.
|
|
35
|
Bennett JM, Muss HB, Doroshow JH, et al: A
randomized multicenter trial comparing mitoxantrone,
cyclophosphamide, and fluorouracil with doxorubicin,
cyclophosphamide, and fluorouracil in the therapy of metastatic
breast carcinoma. J Clin Oncol. 6:1611–1620. 1988.
|
|
36
|
Larsson R and Nygren P: Cytotoxic activity
of topoisomerase II inhibitors in primary cultures of tumor cells
from patients with human hematologic and solid tumors. Cancer.
74:2857–2862. 1994.
|
|
37
|
Klumper E, Pieters R, den Boer ML, et al:
In vitro anthracycline cross-resistance pattern in childhood acute
lymphoblastic leukaemia. Br J Cancer. 71:1188–1193. 1995.
|
|
38
|
Cole SP, Sparks KE, Fraser K, et al:
Pharmacological characterization of multidrug resistant
MRP-transfected human tumor cells. Cancer Res. 54:5902–5910.
1994.
|
|
39
|
Testi R, Mattii L, Di Simone D, et al:
Evaluation of resistance index of several anticancer agents on
parental and resistant P-388 cell lines. Leuk Res. 19:257–261.
1995.
|
|
40
|
Zinzani PL, Storti S, Zaccaria A, et al:
Elderly Aggressive-Histology Non-Hodgkin’s Lymphoma: First-Line
VNCOP-B Regimen Experience on 350 Patients. Blood. 94:33–38.
1999.
|
|
41
|
Doorduijn JK, Spruit P, van Der Holt B, et
al: Etoposide, mitoxantrone and prednisone: a salvage regimen with
low toxicity for refractory or relapsed non-Hodgkin’s lymphoma.
Haematologica. 85:814–819. 2000.
|
